Kerri Fitzgerald

DocwireNews

Despite the varying durability of the different anti-vascular endothelial growth factor (VEGF) agents, there is a positive and clinically meaningful correlation between the number of intravitreal injections in 12 months and the change in mean best-corrected visual acuity (BCVA), according to a study published as part of the American Society of Retina Specialists 2020 Virtual Annual Meeting.Researchers reviewed level 1 evidence for currently approved anti-VEGF injection agents and those likely to undergo review by regulatory authorities, encompassing 23 different injection regimens. Researchers assessed baseline Early Treatment Diabetic Retinopathy Study (ETDRS) Letters, mean number of injections over a 12-month period, and change in ETDRS Letters over 12 months.A total of 6,860 eyes from nine randomized, controlled trials were included. Mean number of injections over 12 months across the studies was 9.4. Eight patients (31.6%; n=2,165) received ranibizumab every four weeks or pro-re-nata (PRN), six (28.6%; n=1,962) received aflibercept every four or eight weeks, four (15.4%; n=1,059) received abicipar every eight or 12 weeks, three (15.8%; n=1,088) received brolucizumab every eight or 12 weeks based on clinical activity, and two (8.7%)&nbsp;received bevacizumab every four weeks or PRN. Mean change in ETDRS Letters was 7.86. The correlation coefficient between the number of injections and mean change in ETDRS Letters was 0.60. Although the agents had different durability, there was a positive and clinically meaningful correlation between the number of injections in 12 months and change in BCVA.&ldquo;Retina specialists should utilize this data in real-world practice, while considering the impact of treatment burden on [patients with wet] AMD,&rdquo; the researchers concluded.Komati R, Hariprasad SM, Eichenbaum DA, et al. Treatment Burden and Vision Analysis of Anti-VEGF Therapies for the Treatment of Neovascular AMD. Presented during the ASRS 2020 Virtual Annual Meeting, July 24-26, 2020.

Brandon Twyford

DESTINY-Breast09 Demonstrates First-Line Superiority of Enhertu Plus Pertuzumab in HER2-Positive Metastatic Breast Cancer

HER2 Breast Cancer

Trodelvy Plus Keytruda Significantly Improves Progression-Free Survival in PD-L1+ mTNBC, Phase III Data Show

Triple-Negative Breast Cancer

Jordana Jampel

Actress Michelle Trachtenberg's Premature Death From Diabetes Reveals Dangers of Chronic Complications

Diabetes

Latest News

Number of Anti-VEGF Injections Correlated with Change in BCVA

ASRS 2020

Despite the varying durability of the different anti-vascular endothelial growth factor (VEGF) agents, there is a positive and clinically meaningful correlation between the ...

About Us

Editorial Policy

Advertising

Contact Us

eNewsletters

Contribute

Career Center

MashupMD

Blood Cancers Today

Cancer Nursing Today

GU Oncology Now

Urban Health Today

Bile Duct Cancer

Colorectal Cancer

Gastroesophageal Cancer

Gastric Cancer

GEP-NETs

GIST

Liver Cancer

Pancreatic Cancer

GI Oncology Now

Anemia

Deep Vein Thrombosis

Essential Thrombocythemia

Hemophilia

Immune Thrombocytopenic Purpura

Myelodysplastic Syndromes

Myelofibrosis

Myeloproliferative Neoplasms

Polycythemia Vera

Pulmonary Embolism

Sickle Cell Disease

Thrombocytopenia

Thrombophilia

Thrombosis

Thrombotic Thrombocytopenic Purpura

Venous Thromboembolism

von Willebrand Disease

Heme Today

Acute Kidney Injury

ADPKD

Anemia and Kidney Disease

Chronic Kidney Disease

COVID-19 and Kidney Disease

Diabetes and Hypertension

End-Stage Renal Disease

Gout

Hyperkalemia

IgAN

Kidney Transplantation

Metabolic Acidosis

Nephrology Times

HR Breast Cancer

Genetics & Breast Cancer

Breast Cancers Today

Atherosclerotic Disease

Atrial Fibrillation

Heart Failure

Hypertension

Interventional Cardiology

Lipid Management

Practice Tips With Dr. Lichaa

Preventive Cardiology

Stroke

Cardiology

Breast Cancer

Gynecologic Cancer

Head and Neck Cancer

Skin Cancer

Oncology

Sleep

Urology

Ophthalmology

— Demodex Blepharitis

Neurology

Rheumatology

Gastroenterology

Pulmonology

Infectious Diseases

— HIV

Health and Wellness

Lupus

Future of Medicine

Orthopedics

Pharmacology

Career News

More

Conferences

CardioNerds

The Sleep Source With Dr. Morse

Rheumatology Rounds With Dr. Maheswaranathan

Partners

Expert Interviews

Subscribe